Brief: Oncolytics Biotech announces first patient treated in Muk Eleven study
Sept 14 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* Oncolytics Biotech announces first patient treated in muk
eleven study
* Oncolytics Biotech - once maximum tolerated dose has been
identified with no associated safety issues, 10 additional
patients will be enrolled at MTD
* Oncolytics Biotech Inc - preliminary data for Muk Eleven
study expected to be available in Q1 2018
Source text for Eikon: ID:nPn55PMqja
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer